IMMX Immix Biopharma, Inc.

IMMX financial statements, revenue, balance sheet, cash flow, and SEC filings

CIK: 1873835 Exchange: Nasdaq SIC: 2834 (Pharmaceutical Preparations) Latest filing: 10-Q filed Nov 12, 2026 Data checked: Nov 13, 2026
Showing 3 of 6 annual and 0 of 23 quarterly periods. Full history available with a free account or via API.

▼ Company Profile

Filer Category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Entity Type
Operating
Public Float
$35.71M (Jun 2025)
Industry (SIC)
2834 Pharmaceutical Preparations
Incorporated
DE
Fiscal Year End
December (1231)
Phone
(888) 958-1084
EIN
454869378
Headquarters
LOS ANGELES, CA, 90064
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.
Former Names: Immix Biopharma, Inc. (2021–2026)

▼ Key Metrics (TTM)

As of Sep 30, 2026
Financials
Revenue
-
Net Income
$-46.26M
Total Assets
$345.95M
Total Equity
$335.06M
Total Debt
-
Free Cash Flow
$-45.24M
Ratios
Return on Equity
-13.8%
Return on Assets
-13.4%
Current Ratio
33.72x
FCF / Assets
-13.1%

▼ FY 2025 Summary Analysis

Annual report ending Dec 31, 2025

Overview and Growth

Immix Biopharma, Inc. recorded fiscal 2025 net loss of $29.44M. The company reported diluted EPS of -$0.89, adding a shareholder-level measure to the absolute income figures considered below. The diluted weighted-average share count was 32.97M, linking total earnings with the per-share result received by shareholders. Compared with 28.29M diluted shares in fiscal 2024, the current 32.97M base was 16.5% higher. Total assets stood at $104.84M, showing the scale of resources supporting revenue, earnings, liquidity, and financing.

Profitability

The company recorded an operating loss of $29.96M after the reported operating expense base. The bottom-line result was a net loss of $29.44M after operating, financing, tax, and other recognized items. EBITDA was negative $29.71M, showing a deficit before interest, taxes, depreciation, and amortization. The pretax result was a loss of $29.40M, establishing the deficit before tax effects. The reported income-tax provision was $37.72K, the amount recognized between pretax income and the final net-income result. The net loss equaled 31.4% of period-end equity, showing the deficit relative to book capital. The loss-to-assets relationship was 28.1%, placing the bottom-line deficit against the company’s resource base. The net loss widened to $29.44M from $21.61M in fiscal 2024.

Liquidity and Capital Structure

The company held $104.84M of assets against $11.04M of liabilities and $93.80M of equity, revealing how the asset base was financed. Current assets were $101.24M against $10.11M of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. The current ratio was 10.01x, with current assets exceeding current liabilities and providing a short-term liquidity cushion. Cash and equivalents totaled $93.93M, identifying the most liquid reported component available within the broader current-asset balance. Measured only with cash and equivalents, coverage of current liabilities was 929.0%, excluding receivables and other current assets. Book equity represented 89.5% of total assets, quantifying the balance-sheet share supported by shareholder capital. The liabilities-to-assets relationship was 10.5%, placing reported obligations against the full positive asset balance. Measured against total assets, cash and equivalents represented 89.6%, a balance-sheet composition measure rather than a liquidity forecast. The asset base changed 356.9% from $22.95M in fiscal 2024, leaving current total assets higher year over year. Reported equity changed 607.8% from $13.25M in fiscal 2024, placing the current capital base higher year over year. The reported cash balance changed 431.2% from $17.68M in fiscal 2024, ending higher year over year.

Cash Flow and Earnings Quality

Operating activities used $23.93M of cash, resulting in an operating cash outflow for the year. Capital spending of $732.92K added to the period’s operating cash use, reinforcing the overall cash deficit after investment for the year. The company recorded a $24.66M cash deficit after capital spending for the period. Relative to total assets, the post-investment cash deficit measured 23.5%. Compared with a $14.60M operating cash outflow in fiscal 2024, the current outflow increased to $23.93M.
Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated .
Sources and calculation details

Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.

Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.

Annual financial statements for Immix Biopharma, Inc.
Metric FY2025 📄 FY2024 📄 FY2023 📄
Income Statement
REVENUE
OPERATING EXPENSES
R&D Expense $16.26M $11.29M $8.74M
SG&A Expense $13.70M $11.38M $7.41M
Operating Income $-29.96M $-22.67M $-16.14M
NON-OPERATING INCOME / EXPENSE
Interest Income $555.53K $1.02M $572.01K
Other Income/Expense $555.53K $1.02M $572.01K
Pretax Income $-29.40M $-21.66M $-15.57M
Income Tax $37.72K $41.04K $26.42K
Net Income $-29.44M $-21.61M $-15.43M
PER SHARE & SUPPLEMENTAL
Diluted EPS $-0.89 $-0.76 $-0.89
Diluted Shares 32.97M 28.29M 17.34M
EBITDA $-29.71M $-22.64M $-16.14M
Depreciation & Amortization $245.75K $32.94K $5.47K
Balance Sheet
ASSETS
Cash & Equivalents $93.93M $17.68M $17.51M
Short-term Investments $6.48M - -
Other Current Assets $150.72K $32.27K $44.58K
Current Assets $101.24M $20.20M $19.79M
PP&E (Net) $2.52M $1.74M $50.18K
Other Noncurrent Assets $20.42K $20.42K -
Noncurrent Assets $3.60M $2.75M $137.41K
Total Assets $104.84M $22.95M $19.93M
LIABILITIES
Accounts Payable $5.44M $5.39M $1.43M
Current Liabilities $10.11M $8.69M $3.72M
Noncurrent Liabilities $933.63K $1.01M $0
Total Liabilities $11.04M $9.70M $3.72M
EQUITY
Common Stock $5.30K $2.76K $2.00K
Additional Paid-in Capital $198.29M $88.37M $69.78M
Retained Earnings $-104.46M $-75.02M $-53.41M
Accumulated OCI $60.16K $-1.06K $134.67K
Total Equity $93.80M $13.25M $16.20M
Total Liabilities & Equity $104.84M $22.95M $19.93M
SUPPLEMENTAL
Shares Outstanding 52.95M 27.54M 19.92M
Check: A − (L + E + Temp. Equity) - - -
Cash Flow Statement
Cash from Operations $-23.93M $-14.60M $-11.37M
Capital Expenditures $732.93K $1.18M $52.09K
Cash from Investing $-7.21M $-1.18M $-52.09K
Cash from Financing $107.39M $15.95M $15.46M
Free Cash Flow $-24.66M $-15.77M $-11.42M
Beginning Cash (CFS) $17.68M $17.51M $13.44M
Net Change in Cash $76.24M $175.79K $4.04M
Effect of FX on Cash $3.84K $-3.62K $33.09K
Calculated Ending Cash $93.93M $17.68M $17.51M
Cash per BS $93.93M $17.68M $17.51M
Cash scope difference (CFS − BS) - - -
Cash per CFS $93.93M $17.68M $17.51M

Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.

Create Free Account Log In
🔒

Quarterly data and charts require a free account

Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.

▼ Frequently Asked Questions

Is Immix Biopharma, Inc. profitable?

No. Immix Biopharma, Inc. reported $-46.26M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.

Does Immix Biopharma, Inc. generate free cash flow?

No. Free cash flow was $-45.24M for trailing twelve months. Operating cash flow was $-44.90M.